US Patent

US8361972 — Pharmaceutical formulations containing an SGLT2 inhibitor

Method of Use · Assigned to Bristol Myers Squibb Co · Expires 2028-03-21 · 2y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects pharmaceutical formulations in the form of capsules or tablets for oral use that contain dapagliflozin or its propylene glycol hydrate for immediate release.

USPTO Abstract

Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2588 —
U-2139 — Farxiga
U-493 — Farxiga
U-1977 — Farxiga
U-2588 —
U-2588 —
U-2139 — Farxiga

Patent Metadata

Patent number
US8361972
Jurisdiction
US
Classification
Method of Use
Expires
2028-03-21
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.